Stockscreener 앱 받기
2.31
7.44%
0.16
시간 외 거래:
2.26
-0.05
-2.16%
전일 마감가:
$2.15
열려 있는:
$2.15
하루 거래량:
156.90K
Relative Volume:
0.79
시가총액:
$6.99M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-3.08
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
+9.48%
1개월 성능:
+5.00%
6개월 성능:
-70.38%
1년 성능:
-88.74%
1일 변동 폭
$2.15
$2.38
1주일 범위
$1.98
$2.38
52주 변동 폭
$1.98
$22.50
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.31 | 7.23M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Is Tourmaline Bio Inc. stock ready for a breakoutFree Alpha Driven Watchlist With Alerts - Newser
MUSTANG BIO, INC. SEC 10-Q Report - TradingView
REPEATTevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions - uk.finance.yahoo.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KALA BIO, Inc. SEC 10-Q Report - TradingView
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioVie Inc. Announces Pricing of $12 Million Public Offering - The Manila Times
Gossamer Bio Expands Team with 168,750 Share Options Grant at $2.16 Exercise Price - Stock Titan
INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire
Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth - Stock Titan
Layoff Tracker: 60 Biotech Staff Lose Jobs as Poseida, Alltrna Reduce Workforce - BioSpace
Nuvation Bio Reports 1,043% YoY Sales Growth, Exceeds Revenue Estimates with $4.8 Million in GAAP Revenue - AInvest
Palisade Bio Reports 100% Clinical Response in Phase 1b - GlobeNewswire
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
New Lung Cancer Drug IBTROZI Gains FDA Approval, Reaches 70 Patients in First 7 Weeks - Stock Titan
How sentiment analysis helps forecast Instil Bio Inc.Insider Strategy for High Conviction Picks - Newser
Can technical indicators confirm Belite Bio Inc Depositary Receipt’s reversalFree Weekly Return Pick Forecast Reports - Newser
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc. - Bluefield Daily Telegraph
7 Dividend Stocks for 2025 — Some Pay Over 8%, Some Just Refuse to Die - The Globe and Mail
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
Q32 Bio Secures FDA Fast Track for Alopecia Treatment as Phase 2 Trial Advances with $54.8M Runway - Stock Titan
Climb Bio Inc. stock daily chart insightsFree ROI Driven Equity Selection With Safety - Newser
Adicet Bio's Gamma Delta T Cell Therapy Updates Coming at Major Growth Conference - Stock Titan
INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan
What drives Upstream Bio Inc. stock priceDynamic profit expansion - Jammu Links News
Should I hold or sell Third Harmonic Bio Inc. stock in 2025Unlock expert market analysis instantly - Jammu Links News
Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - jammulinksnews.com
How many analysts rate bluebird bio Inc. as a “Buy”Low Risk Alerts Backed By Experts - Jammu Links News
10 Penny Stocks That Will Skyrocket - Insider Monkey
What makes INmune Bio Inc. stock price move sharplyBreakout Stocks Tracker With High Returns - Jammu Links News
Nasdaq Compliance Regained: Passage Bio Stock Price Meets Minimum Requirement - AInvest
INmune Bio to Present Q2 2025 Financial Results and Key Clinical-Stage Updates on August 7 - Stock Titan
What are the latest earnings results for Climb Bio Inc.Advanced Screener Growth Plan For Fast Growth - Jammu Links News
How Palisade Bio Inc. stock performs during market volatilityPattern Recognition Based Market Move Prediction - Newser
What institutions are buying Korro Bio Inc. stock nowMarket Stability and Long-Term Growth Outlook - Newser
Is 2seventy bio Inc. forming a reversal patternFree Weekly Growth Stock Entry Point Alerts - Newser
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - Jammu Links News
Is 2seventy bio Inc. stock overvalued or undervaluedOverwhelming profit margins - jammulinksnews.com
What are analysts’ price targets for Korro Bio Inc. in the next 12 monthsBreakout portfolio performance - Jammu Links News
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - uk.finance.yahoo.com
Moving Average Trends for 2seventy bio Inc. Stock: What They IndicateFree Professional Trading Signals - Newser
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
What drives INmune Bio Inc. stock priceSignificant capital appreciation - PrintWeekIndia
Adicet Bio Expands Autoimmune Disease Trial: First Systemic Sclerosis Patient Receives Novel T Cell Therapy - Stock Titan
Global Oncology Leader Nuvation Bio Sets Q2 Earnings Call: Latest Cancer Treatment Progress - Stock Titan
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million - GlobeNewswire
What drives Adicet Bio Inc. stock priceFree Market Dynamics Reports - Jammu Links News
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):